Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282581 | 0.89 | TSHR (0.54) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| Ethylene SCHEMBL6410194 | 0.87 | TSHR (0.51) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14448347 | 0.86 | TSHR (0.50) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14582854 | 0.85 | TUBB4A (0.43) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14448350 | 0.85 | MAPK1 (0.53) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3247280 | 0.85 | CYP3A4 (0.49) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14582856 | 0.83 | SMPD1 (0.49) | MAPTACHESMN1; SMN2BCHE | |
| SCHEMBL3854017 | 0.81 | TUBB4A (0.48) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8337903 | 0.81 | SMPD1 (0.48) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8323174 | 0.81 | SMPD1 (0.48) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408852-B2 | Method of lowering serum uric acid levels with (S)-tofisopam | PHARMOS CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | PHARMOS CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | ATIC, NPPA, XPNPEP1 | TSHR 1549/4885CYP1A2 1854/4885CYP3A4 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.